US Patent

US11261447 — Methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression

Method of Use · Assigned to Alnylam Pharmaceuticals Inc · Expires 2038-11-20 · 13y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods of using RNAi agents to inhibit expression of the HAO1 gene and treat subjects with PH1.

USPTO Abstract

The invention relates methods of using RNAi agents to inhibit expression of HAO1 and methods of treating subjects having, e.g., PH1.

Drugs covered by this patent

lumasiran-sodium (LUMASIRAN SODIUM)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2995`	—	lumasiran-sodium

Patent Metadata

Patent number: US11261447
Jurisdiction: US
Classification: Method of Use
Expires: 2038-11-20
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Alnylam Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.